Literature DB >> 17081806

Natural history of patients hospitalized for management of cirrhotic ascites.

Ramon Planas1, Silvia Montoliu, Belen Ballesté, Monica Rivera, Mireia Miquel, Helena Masnou, Jose Antonio Galeras, María D Giménez, Justiniano Santos, Isabel Cirera, Rosa María Morillas, Susanna Coll, Ricard Solà.   

Abstract

BACKGROUND & AIMS: Since the International Ascites Club published the diagnostic criteria of refractory ascites (RA) and hepatorenal syndrome (HRS), there have been few studies assessing the natural history of ascites. The aims of this study were to define the natural history of cirrhotic ascites and to identify prognostic factors for dilutional hyponatremia (DH), RA, HRS, and survival.
METHODS: Two hundred sixty-three consecutive cirrhotic patients were followed for 40.9 +/- 2.6 months after their first significant ascites.
RESULTS: During follow-up 74 (28.1%) patients developed DH, 30 (11.4%) RA (diuretic-resistant in 2 cases and diuretic-intractable because of the development of diuretic-induced complications in 28 cases), and 20 (7.6%) HRS (type 1, 7; type 2, 13). The 5-year probability of DH, RA, and HRS development was 37.1%, 11.4%, and 11.4%, respectively. The probability of survival at 1 and 5 years was 85% and 56.5%, respectively. The independent predictors for survival were baseline age, baseline Child-Pugh score, and DH development. The 1-year probability of survival after developing DH, RA, and type 2 HRS was 25.6%, 31.6%, and 38.5%, respectively. In contrast, the mean survival was only 7 +/- 2 days in those patients developing type 1 HRS.
CONCLUSIONS: (1) The survival of cirrhotic patients with first episode of ascites is relatively high, and it is mainly influenced by age and Child-Pugh score at the time of ascites decompensation, as well as by DH development. (2) The probability of RA and HRS development is relatively low, but they are associated with a poor prognosis.

Entities:  

Mesh:

Year:  2006        PMID: 17081806     DOI: 10.1016/j.cgh.2006.08.007

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  74 in total

Review 1.  Hepatorenal syndrome: Update on diagnosis and treatment.

Authors:  Olga Baraldi; Chiara Valentini; Gabriele Donati; Giorgia Comai; Vania Cuna; Irene Capelli; Maria Laura Angelini; Maria Ilaria Moretti; Andrea Angeletti; Fabio Piscaglia; Gaetano La Manna
Journal:  World J Nephrol       Date:  2015-11-06

Review 2.  New concepts on the clinical course and stratification of compensated and decompensated cirrhosis.

Authors:  Gennaro D'Amico; Alberto Morabito; Mario D'Amico; Linda Pasta; Giuseppe Malizia; Paola Rebora; Maria Grazia Valsecchi
Journal:  Hepatol Int       Date:  2017-07-05       Impact factor: 6.047

3.  Continuous furosemide infusion in the management of ascites.

Authors:  Nicholas A Rogers; Samir Gupta; Jennifer A Cuthbert
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

4.  Potential Effectiveness of Tolvaptan to Improve Ascites Unresponsive to Standard Diuretics and Overall Survival in Patients with Decompensated Liver Cirrhosis.

Authors:  Tomoharu Yamada; Takamasa Ohki; Yuki Hayata; Yuki Karasawa; Satoshi Kawamura; Daisaku Ito; Kentaro Kojima; Michiharu Seki; Nobuo Toda; Kazumi Tagawa
Journal:  Clin Drug Investig       Date:  2016-10       Impact factor: 2.859

Review 5.  Paracentesis-induced circulatory dysfunction: a primer for the interventional radiologist.

Authors:  Aaron J Lindsay; James Burton; Charles E Ray
Journal:  Semin Intervent Radiol       Date:  2014-09       Impact factor: 1.513

6.  Clinical value of urinary retinol-binding protein in ascites due to cirrhosis.

Authors:  Yujing Xia; Jingjing Li; Sainan Li; Tong Liu; Yuqing Zhou; Qin Yin; Jianrong Wang; Wenxia Lu; Rong Zhang; Yuanyuan Zheng; Fan Wang; Jie Lu; Kan Chen; Weiqi Dai; Yingqun Zhou; Chuanyong Guo
Journal:  Exp Ther Med       Date:  2017-09-22       Impact factor: 2.447

7.  Development and Validation of a Patient-Reported Outcome Measurement for Symptom Assessment in Cirrhotic Ascites.

Authors:  Myrte Neijenhuis; Tom J G Gevers; Thomas D Atwell; Tim J Gunneson; Amanda C Schimek; Wietske Kievit; Joost P H Drenth; Patrick S Kamath
Journal:  Am J Gastroenterol       Date:  2018-03-20       Impact factor: 10.864

Review 8.  The Kidney in Pediatric Liver Disease.

Authors:  Robyn Greenfield Matloff; Ronen Arnon
Journal:  Curr Gastroenterol Rep       Date:  2015-09

9.  Cirrhotic ascites review: Pathophysiology, diagnosis and management.

Authors:  Christopher M Moore; David H Van Thiel
Journal:  World J Hepatol       Date:  2013-05-27

Review 10.  Management of ascites.

Authors:  Fedja A Rochling; Rowen K Zetterman
Journal:  Drugs       Date:  2009       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.